Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 15 of 15 for “"Serglycin"”.

  1. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan.

    … Masayuki Miyasaka. A Novel Ligand for CD44 Is Serglycin, a Hematopoietic Cell Lineage-specific Proteoglycan : POSSIBLE INVOLVEMENT IN LYMPHOID CELL ADHERENCE AND ACTIVATION. The Journal of Biological Chemistry. 1995; Vol.270:pp7437-pp7444. © the American Society for Biochemistry and Molecular …

    osaka Repository record for A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. (opens in a new tab) Download PDF for A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. (opens in a new tab)

  2. Bioengineered growth factor delivery molecules for vascularisation and wound healing

    … of their glycosaminoglycan (GAG) chains. Serglycin is an intracellular PG, which has eight GAG attachment sites. Unlike other PGs, serglycin can be decorated with heparin, heparan sulphate (HS), chondroitin sulphate (CS) and/or dermatan sulphate (DS). Through these various GAG chains, …

    unsw Repository record for Bioengineered growth factor delivery molecules for vascularisation and wound healing (opens in a new tab)

  3. Platelet interactions with Proteoglycans for Vascular Applications

    … types of PGs were identified in human platelets, serglycin, betaglycan and syndecan-1. Serglycin was found to be a heterogeneous population with molecular weights between 50 and 250 kDa, as well as a band at 10 kDa. Betaglycan was also found to be a heterogeneous population with molecular weights …

    unsw Repository record for Platelet interactions with Proteoglycans for Vascular Applications (opens in a new tab)

  4. Estimating the Prevalence and Unravelling the Disease Mechanisms of GNE Myopathy

    … Second, proteomic analyses identified serglycin as a potential circulating biomarker of GNEM. Reduced serum serglycin in patients was accompanied by intracellular accumulation in GNEM cellular models. Further investigation implicated disruptions in membrane trafficking, Golgi function, …

    ottawa-retro Repository record for Estimating the Prevalence and Unravelling the Disease Mechanisms of GNE Myopathy (opens in a new tab)

  5. Complement in Disease - Extracellular Proteins as Complement Regulators

    … demonstrated in vivo. We further showed that serglycin, a proteoglycan secreted by multiple myeloma cells, inhibits the classical and lectin pathways of complement and that cell surface expression of serglycin leads to protection of these cells from complement attack. This might interfere with …

    lund Repository record for Complement in Disease - Extracellular Proteins as Complement Regulators (opens in a new tab) Download PDF for Complement in Disease - Extracellular Proteins as Complement Regulators (opens in a new tab)

  6. Einfluss des Cell Adhesion Signaling bei der Resistenz gegenüber Tyrosinkinase-Inhibitoren in der chronisch myeloischen Leukämie

    … insbesondere der Matrixmoleküle Fibronektin und Serglycin, auf. Ziel dieser Arbeit war es daher, die Auswirkungen der Deregulation auf die matinib-Resistenz zu untersuchen. Es zeigte sich eine Herunterregulation der Expression auf mRNA- und Proteinebene in resistenten K-562-Zellen im Vergleich zu …

    cau-kiel Repository record for Einfluss des Cell Adhesion Signaling bei der Resistenz gegenüber Tyrosinkinase-Inhibitoren in der chronisch myeloischen Leukämie (opens in a new tab)

  7. Understanding the Consequences of Deficient Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1) Expression in Congenital Myasthenic Syndromes (CMS) and Elucidating New Therapeutic Strategies

    … to restore glycan homeostasis, and identifies serglycin as a potential biomarker. These discoveries advance the mechanistic understanding of glycosylation dependent neuromuscular disease and lay the groundwork for targeted therapeutic development in GFPT1 CMS and related disorders.

    ottawa-retro Repository record for Understanding the Consequences of Deficient Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1) Expression in Congenital Myasthenic Syndromes (CMS) and Elucidating New Therapeutic Strategies (opens in a new tab)

  8. Effect of GM-CSF on RNA and protein in human peripheral blood granulocytes.

    … mRNA. Probing granulocyte total RNA with serglycin proteoglycan intron sequences revealed that transcriptional elongation may be the rate-limiting step. (iii) An unknown 26--27 kDa protein demonstrated the largest increase in [ 35S]methionine-labeling (2--4 fold) with GM-CSF-stimulation. …

    ottawa-retro Repository record for Effect of GM-CSF on RNA and protein in human peripheral blood granulocytes. (opens in a new tab)

  9. AN INVESTIGATION OF THE EFFECT OF CHITOSAN-BASED MATERIALS ON SKIN WOUND HEALING

    … syndecans-1 and -4 and HS with the exception of serglycin. Thus, CH-Arg-based materials have the potential to mimic HS and promote skin wound healing with respect to enhancing re-epithelialisation and the formation of ECM molecules.

    unsw Repository record for AN INVESTIGATION OF THE EFFECT OF CHITOSAN-BASED MATERIALS ON SKIN WOUND HEALING (opens in a new tab)

  10. Μελέτη της έκφρασης και του ρόλου της σεργλυκίνης στις κακοήθειες

    Serglycin (SG) is the major proteoglycan of hematopoietic origin cells and contributes to the regulation of several inflammatory proteins. Moreover, SG has a significant role in the biology of Multiple Myeloma; It inhibits the activation of the classical and the lectin pathway of complement system. …

    greece Repository record for Μελέτη της έκφρασης και του ρόλου της σεργλυκίνης στις κακοήθειες (opens in a new tab)

  11. Novel enzymatic processing of perlecan by mast cells: a potential role in angiogenesis

    … cell lines were found to produce and secrete serglycin, which was detected as two protein cores (11 and 13 kDa) decorated with both CS and HS. Novel finding in this thesis is that the model mast cells are capable of producing and secreting perlecan decorated with HS and CS, which was detected …

    unsw Repository record for Novel enzymatic processing of perlecan by mast cells: a potential role in angiogenesis (opens in a new tab)

  12. Μελέτη ρυθμιστικών μηχανισμών έκφρασης βιομορίων, λειτουργικών ιδιοτήτων και μορφολογικών χαρακτηριστικών των καρκινικών κυττάρων μαστού

    … the transmembrane syndecans and intracellular serglycin, several MMPs, plasminogen activation system components and receptor tyrosine kinases. These data clearly demonstrate that ERβ plays a crucial role in mediating cell behavior and ECM composition of the highly aggressive MDA-MB-231 cells …

    greece Repository record for Μελέτη ρυθμιστικών μηχανισμών έκφρασης βιομορίων, λειτουργικών ιδιοτήτων και μορφολογικών χαρακτηριστικών των καρκινικών κυττάρων μαστού (opens in a new tab)

  13. Comparison of Different Mast Cell Types and Their Responses to IL-33 via High Resolution Mass Spectrometry

    … granule protein expression with the exception of serglycin (Srgn) which is critical to granule development, integrity and storage of effector molecules including histamine and serotonin which are vital to MC function.<br/><br/>IL-33-mediated extensive remodelling of the FLMC, BMMC and PMC …

    dundee Repository record for Comparison of Different Mast Cell Types and Their Responses to IL-33 via High Resolution Mass Spectrometry (opens in a new tab)

  14. Ο ρόλος της σεργλυκίνης στη ρύθμιση του συμπληρώματος και στην έκφραση των μεταλλοπρωτεϊνασών σε μυελωματικά πλασματοκύτταρα: βιοχημική, μοριακή και κλινικοεργαστηριακή προσέγγιση

    Η σεργλυκίνη (SG) είναι μια πρωτεογλυκάνη που εκφράζεται και εκκρίνεται από το σύνολο σχεδόν των αιμοποιητικών κυττάρων, ενώ αποτελεί την κύρια πρωτεογλυκάνη η οποία εκκρίνεται από τις κυτταρικές σειρές πολλαπλού μυελώματος (ΠΜ). Έχει βρεθεί ότι η SG συμμετέχει στη ρύθμιση πληθώρας παραγόντων που …

    greece Repository record for Ο ρόλος της σεργλυκίνης στη ρύθμιση του συμπληρώματος και στην έκφραση των μεταλλοπρωτεϊνασών σε μυελωματικά πλασματοκύτταρα: βιοχημική, μοριακή και κλινικοεργαστηριακή προσέγγιση (opens in a new tab)